Blue Horseshoe Stocks

Blue Horseshoe Stocks: Reviewing Friday’s Session

Pazoo, Inc. PZOO

PZOO continued its recent pattern of offering up solid intraday gain opportunities with its performance on Friday. For some of our newest members- we refocused upon PZOO on April 1st. From that time up until Friday morning we’d seen positive intraday swings of 37% (04/01), 39% (04/06), 33% (04/07), 14% (04/08), and 40% (04/09).

On Friday, the stock presented another 15% swing as it traded in a range from .0087-.01. One thing we can definitely take away from these strong daily performances is that PZOO is building a heck of a chart. One look at the snapshot below and you can see just what we mean.

PZOO did a great job last week of bullishly registering a higher low each day, so we’ll be very interested to see how the chart reacts to start things off this week. Ideally speaking, we want to see the stock maintain support at or above the 50DMA (.008) moving forward, and for it to make another run at penny-plus territory. We’ll be sure to keep our readers updated on the situation.

Frontline, Ltd. FRO

An old favorite of ours over the years, FRO was an inclusion in Friday’s extended watchlist, and it seems that we re-alerted this stock just in the nick of time.

The stock was able to open at and move up from a recent area of heavy resistance around the 2.40-mark, and from that low we saw a move to 2.67. While it amounts to just an 11% intraday gain, it held greater significance in that it is the first time FRO’s PPS exceeded its current 50DMA since the middle of February.

The move also paved the way for the stock to continue gapping up in this morning’s premarket, currently trading in the high 2.80’s. We’re definitely going to keep an eye peeled for this stock as we kick off a new trading week. Bullish indicators presently forming on the chart suggest that further chances to profit may be on the immediate horizon.

Petroleo Brasiliero, S.A. (Petrobras) PBR – Options

The PBR Options Chain has been a veritable gold mine for us over the past couple of weeks. We began with the $6 and $6.50 Calls the week before last, and as PBR continued to trend up we rolled our targeted strike prices up early last week to the Weekly and 05/01 $7 Calls, and all contracts concerned made appreciable moves, affording us the chance at percentage gains nearing the neighborhood of 1000%

Then on Friday, we did it again. We mentioned our interest in rolling our strike price up again to the 7.50-level, either in puts or calls depending on which way the trend wanted to carry the stock. It became quickly apparent that the bullish side would prevail, and we subsequently witnessed an intraday run from .09-.22. That’s a healthy rip totaling 144%

That calls for congratulations to anyone who has used PBR to leverage some hefty gains along with us of late; even as many on Wall Street have turned their backs on the Brazilian oil mega-producer.

We’ll continue to stay hot on its trail as long as it continues to serve us up premium chances, so stay tuned!

Blue Horseshoe Stocks: Recapping VLTC, PZOO & More

Pazoo, Inc. PZOO

Price action on PZOO has continued to offer up quick-strike gain opportunities for us over the past several sessions,. as well as making an excellent overall move.

To quickly recap: We tagged this play on Wednesday, April 1st, and were shown a solid 37% intraday run from .0052-.0071. The stock then retraced back to a low of .0049 on Monday morning, and from there it has managed to register higher highs and higher lows all week long.

Monday’s high was .0068, marking a 39% intraday thrust. On Tuesday, PZOO traded in a range from .006-.008 (+33%). Wednesday’s move was a bit more subdued, at 14% (.007-.008), but yesterday, things really took off. From an early low of .0078, PZOO cracked into Pennyland, hitting a high of .0109! That totaled an intraday gain of 40%, and a very respectable overall intraweek spike of 122% from our observed low of .0049 on Monday.

We’ll have our eyes on the press wires for updates, and we’ll be sure to keep our readers updated on all the action.

Updated PZOO Video Chart:

Visit PZOO @ www.pazoo.com
The new site dedicated to its marijuana testing arm is located @ cannabisking.pazoo.com

Voltari Corp. VLTC

It was the middle of last week when we alerted VLTC in our morning report. We saw a low of 2.18 on Thursday morning, and the stock has trended up quite nicely since then.

By Monday afternoon it ran more than 115% up to a high of 4.73, and then yesterday the stock really exploded into blue skies. An intraday run from 4.02-6.18 was good for gains of up to 54%, and this morning’s premarket high of 6.49 represents an overall increase of 198%

All in all, we’ve got to say that VLTC has been quite the performer over the past week.

Petroleo Brasiliero, S.A. (Petrobras) PBR – Options

Our ongoing coverage of the PBR options chain has been ceaselessly providing us with premium chances for profit. Our readers will recall that after a mountain of success with $6 and $6.50 Calls last week, earlier this week we rolled up our strike range slightly zeroing in on both Weekly and 05/01 $7 Calls.

Yesterday’s daily high of 7.56 provided sufficient leverage to catapult the Weekly $7 Calls to new impressive highs. The Weekly $7’s have traded in a range from .06-.66, an enormous 900% jump!

PBR is gapping up this morning, and for potential daytrading opportunities we’re going to focus upon both the $7.50 Weekly Calls, *and* $7.50 Weekly Puts, depending on which way momentum carries the trend.

Extended Watchlist:
QTM, FRO, CBMX, HERO, ZNGA

Blue Horseshoe Stocks: PBR, INO, RAD Reviews & More

Petroleo Brasiliero, S.A. (Petrobras) PBR – Options

PBR has continued to perform this week after we caught it coming off its 52-week lows two Thursday’s ag o. At that time one of our main areas of interest was the 05/01 $6.50 Calls, which we subsequently observed trading at a low of .22. This week they’ve attained a high of .71, marking off a tidy 222% move.

The last time we touched upon PBR options on Monday morning, it was in the process of pushing even higher, so we suggested the possibility of rolling up our strike price to both the Weekly and May 1st $7 Calls, and that idea turned out to be a good one as well.

We’ve witnessed a trading range on the Weekly $7’s from .06 -.25, a whopping 316%, while the May 1st $7’s enjoyed an 87% run from .30 to .56.

Inovio Pharmaceuticals, Inc. INO

INO stands among those stocks that we have covered the most over the years. An INO tag search of our archives yields no less than 30 results. We re-flagged it in yesterday’s premarket report and the timing was quite fortuitous.

Yesterday morning the company had announced it had been selected as the leader of a $45M DARPA program to develop practical treatments for the Ebola virus. It fueled a continued rise off of recent lows, and this morning’s news could contribute to that as well. >> READ PR

INO heralded positive results from one of its studies, a DNA-based immunotherapy for the treatment of head and neck cancer. According to the CFO, the “initial data set from Inovio’s first cancer study provides encouraging evidence that we are on an important path to better optimized immunotherapy products.” >> READ PR

We’ll continue to keep watch over INO in the wake of these major developments.

Molycorp, Inc. MCP

MCP started showing up on our scanner back on March 23rd and 24th, when it was trading around .38. It retraced back to its 52-week low of .32 on the 27th.

After reappearing on our extended watchlist yesterday, it has traded as high as .62 in the premarket today; from a low of .484 that’s a 28% move up.

At .62, MCP had shown us a 94% overall move from its ultimate low set just the week before last. With gold and other precious metal prices on the rise again, we’ll continue to track MCP for more potential gain opportunities.

Rite-Aid Corp. RAD

We also wanted to make a quick mention of RAD. We tagged the stock for tracking back on December 4th and on that day we observed the lowest price the stock has traded at since then (5.48).

Since that time the stock has crept (and sometimes leaped) its way up the chart; it broke its 50DMA in early March, and managed break the $9-mark last Thursday, and then again yesterday. At Thursday’s high of 9.07, we had witnessed a total gain of 65%

Wall Street analysts are giving RAD high marks, and the stock is also receiving a 96% Overall “Buy” Rating at BARCHART.COM so we’ll certainly want to keep a close watch on RAD moving forward in the event that it sustains the bullish patterns it has been exhibiting over the past several months.

Extended Watchlist:
EXEL, OPXA, WPCS, MPET, MSTX, SLTD

Blue Horseshoe Stocks: VLTC, PZOO Updates & More

Pazoo, Inc. PZOO

A week ago today, we revisited PZOO in our morning report and were instantly rewarded for our good timing with a run from .0052 to .0071, a 37% intraday move. We let our readers know that we’d be monitoring the stock more closely moving forward, and this week it has once again begun an upswing.

After consolidating off of that initial pop, it ultimately found support at .0049 on Monday before turning northward once again and rebounding to .0068 (+39%).

It continued to set higher highs and higher lows during yesterday’s session as it traded in a range from .006-.008 (+33%), and finally cracked above its 50-day moving average, which was something we were looking to have happen.

To get an in-depth view of the current PZOO chart, click or tap on the graphic below:

Visit PZOO @ www.pazoo.com
The new site dedicated to its marijuana testing arm is located @ cannabisking.pazoo.com

Voltari Corp. VLTC

It was also last Wednesday that we alerted VLTC via our extended watchlist, and it didn’t take very long for this play to make a huge move.

VLTC touched a low of 2.18 on Thursday at the end of the short week, followed by a run to as high as 4.73 on Monday. That registered as a 117% session-over-session rip, and came on nearly seven times the 30-day average trading volume. A tip of the cap to anyone who took advantage of that rapid, hefty upswing!

Extended Watchlist:
TRBD, MCP, VRNG, INO, PSTR, DRYS

Blue Horseshoe Stocks: PMCB Special Report

PharmaCyte Biotech, Inc. PMCB

As we kick off the start of a new trading week, our point of focus is going to be PMCB, a clinical stage biopharma company. The Biopharma/Biotech sector has been enjoying a resurgence of late, evidenced by many such plays that we’ve already run across this year. What sets PMCB apart from the rest is the versatility of its flagship product, which we believe has significant disruptive potential in the marketplace upon further development.

The nature of PMCB‘s patented Cell-in-a-Box® technology lends to its high development potential, as it is a cellular treatment delivery method which could theoretically be utilized for virtually limitless applications. It can be generically referred to as a ‘cellulose-based live cell encapsulation technology’, but to explain exactly what that means to the average person requires a bit more detail.

Cellulose is an organic polymer which is the most abundant such compound in nature, being found in varying quantities in the cell walls of all plants. It is chemically inert, and its insolubility in the human body makes it an ideal carrier for potential treatments. Microscopic capsules constructed of cellulose are filled with living cells, either lab-engineered or cultured from natural compounds, and introduced into the body. The capsules have micropores which do not allow for the escape of the contained cells, but are sufficient in size to facilitate introduction of essential nutrients and beneficial substances produced by the cells. >> LEARN MORE

PMCB has several irons in the fire with Cell-in-a-Box®. It has been granted orphan-drug status by the FDA relating to the treatment of advanced pancreatic cancer, and the company currently has three separate Phase II trials underway testing its efficacy from multiple angles. >> LEARN MORE

In addition, the company has preclinical trials involving its technology’s implementation using cannabinoids, an active compound found in marijuana, which has the potential to help PMCB expand into another trendy sector. There are a number of other treatments in the preclinical phase, including those that treat diabetes, as well as brain and breast cancer.

Goldman Smallcap Research recently released a report on PMCB wherein senior analyst Rob Goldman referred to the company as a “prototypical acquisition target”. Based on what we ourselves have learned about PharmaCyte and the future potential of its many treatments, we’d find it hard to deny the possibility of PMCB getting picked up by a large pharmaceutical company at some point. >> GOLDMAN REPORT

FDA’s Record Approvals Bode Well for PharmaCyte’s Cancer Treatments (Tue 8:45AM EDT)
_____________________

CHART:

We can also see potential in the chart in the near-term. PMCB recently ran off of its 52-week low of .10, making a solid move to .16. Yesterday the stock began to consolidate off of that spike, and there could be a considerable bounce once the stock finds support. We’ll be looking for that to happen at or above the current 50DMA of .12. Beyond that, if PMCB can break resistance at .16, the next patch is sitting at the 200DMA, just shy of .20. The stock was trading at that level back in January, and a return there from current prices would leave us open to gains in the neighborhood of 40% or more.

We’ve also prepared a video presentation of the chart for your convenience:

Learn More About PMCB @ PharmacyteBiotech.com